Prognostic value of tumor-associated macrophages in pancreatic cancer: a meta-analysis

References

• Raraty MGT, Magee CJ, Ghaneh P, Neoptolemos JP. New techniques and agents in the adjuvant therapy of pancreatic cancer. Acta Oncol. 2002;41:582–595. doi:10.1080/028418602321028184
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Teng F, Tian WY, Wang YM, et al. Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis. J Hematol Oncol. 2016;9:8. doi:10.1186/s13045-015-0231-426851944
   PubMed Web of Science ®Google Scholar
• Genard G, Lucas S, Michiels C. Reprogramming of tumor-associated macrophages with anticancer therapies: radiotherapy versus chemo- and immunotherapies. Front Immunol. 2017;8. doi:10.3389/fimmu.2017.00828
   PubMed Web of Science ®Google Scholar
• Ohno S, Inagawa H, Dhar DK, et al. Role of tumor-associated macrophages (TAM) in advanced gastric carcinoma: the impact on FasL-mediated counterattack. Anticancer Res. 2005;25:463–470. 15816613
   PubMed Web of Science ®Google Scholar
• Yuan X, Zhang J, Li D, et al. Prognostic significance of tumor-associated macrophages in ovarian cancer: a meta-analysis. Gynecol Oncol. 2017;147:181–187. doi:10.1016/j.ygyno.2017.07.00728698008
   PubMed Web of Science ®Google Scholar
• Dai F, Liu L, Che G, et al. The number and microlocalization of tumor-associated immune cells are associated with patient’s survival time in non-small cell lung cancer. BMC Cancer. 2010;10:220. doi:10.1186/1471-2407-10-66320487543
   PubMed Web of Science ®Google Scholar
• Zhou Q, Peng R, Wu X, et al. The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer. J Transl Med. 2010;8:13. doi:10.1186/1479-5876-8-7220141634
   PubMed Web of Science ®Google Scholar
• Ino Y, Yamazaki-Itoh R, Shimada K, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Brit J Cancer. 2013;108:914–923. doi:10.1038/bjc.2013.3223385730
   PubMed Web of Science ®Google Scholar
• Kurahara H, Shinchi H, Mataki Y, et al. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res. 2011;167:e211–e219. doi:10.1016/j.jss.2009.05.02619765725
   PubMed Web of Science ®Google Scholar
• Knudsen ES, Vail P, Balaji U, et al. Stratification of pancreatic ductal adenocarcinoma: combinatorial genetic, stromal, and immunologic markers. Clin Cancer Res. 2017;23:4429–4440. doi:10.1158/1078-0432.CCR-17-016228348045
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the newcastle-ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–605. doi:10.1007/s10654-010-9491-z20652370
   PubMed Web of Science ®Google Scholar
• Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 2004;23:2815–2834.
   Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. doi:10.1186/1745-6215-8-1617555582
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560. doi:10.1136/bmj.327.7414.55712958120
   PubMed Web of Science ®Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–1101. Published by: International Biometric Society Stable Available from: http://www.jstor.org/stable/2533446. Accessed March 20, 2013. 7786990
   PubMed Web of Science ®Google Scholar
• Hou Y, Chao Y, Tung H, Wang H, Shan Y. Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma. Cancer-Am Cancer Soc. 2014;120:2766–2777.
   PubMed Web of Science ®Google Scholar
• Takakura K, Ito Z, Suka M, et al. Comprehensive assessment of the prognosis of pancreatic cancer: peripheral blood neutrophil-lymphocyte ratio and immunohistochemical analyses of the tumour site. Scand J Gastroenterol. 2016;51:610–617. doi:10.3109/00365521.2015.112151526679084
   PubMed Web of Science ®Google Scholar
• Chen SJ, Zhang QB, Zeng LJ, et al. Distribution and clinical significance of TAMs in pancreatic ductal adenocarcinoma: a retrospective analysis in China. Curr Oncol. 2015;22:11–19. doi:10.3747/co.22.2150
   PubMed Web of Science ®Google Scholar
• Liu Q, Niu Z, Li Y, et al. Immunoglobulin G4 (IgG4)-positive plasma cell infiltration is associated with the clinicopathologic traits and prognosis of pancreatic cancer after curative resection. Cancer Immunol Immunother. 2016;65:931–940. doi:10.1007/s00262-016-1853-227271551
   PubMed Web of Science ®Google Scholar
• Hutcheson J, Balaji U, Porembka MR, et al. Immunologic and metabolic features of pancreatic ductal adenocarcinoma define prognostic subtypes of disease. Clin Cancer Res. 2016;22:3606–3617. doi:10.1158/1078-0432.CCR-15-188326858311
   PubMed Web of Science ®Google Scholar
• Yoshikawa K, Mitsunaga S, Kinoshita T, et al. Impact of tumor-associated macrophages on invasive ductal carcinoma of the pancreas head. Cancer Sci. 2012;103:2012–2020. doi:10.1111/j.1349-7006.2012.02411.x22931216
   PubMed Web of Science ®Google Scholar
• Wang WQ, Liu L, Xu HX, et al. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma. Br J Surg. 2016;103:1189–1199. doi:10.1002/bjs.1018727256393
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Mitsunaga S, Yoshikawa K, et al. Prognostic impact of M2 macrophages at neural invasion in patients with invasive ductal carcinoma of the pancreas. Eur J Cancer. 2014;50:1900–1908. doi:10.1016/j.ejca.2014.04.01024835032
   PubMed Web of Science ®Google Scholar
• Diana A, Wang LM, D’Costa Z, et al. Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget. 2016;7:72819. 27637082
   PubMedGoogle Scholar
• Hu H, Hang J, Han T, Zhuo M, Jiao F, Wang L. The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer. Tumor Biology. 2016;37:8657–8664. doi:10.1007/s13277-015-4741-z26738860
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–899. doi:10.1016/j.cell.2010.01.02520303878
   PubMed Web of Science ®Google Scholar
• Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application. J Hematol Oncol. 2017;10:12–58. doi:10.1186/s13045-016-0381-z28077173
   PubMed Web of Science ®Google Scholar
• Hanchen L, Xueli F, Jeanmarie H. Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem. 2010;101:805–815.
   Google Scholar
• Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423–1437. doi:10.1038/nm.339424202395
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang S, Wang Q, Zhang X. Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein. J Hematol Oncol. 2017;10:36. doi:10.1186/s13045-017-0408-028143526
   PubMed Web of Science ®Google Scholar
• Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol. 2009;27:451. doi:10.1146/annurev.immunol.021908.13253219105661
   PubMed Web of Science ®Google Scholar
• Takeya M, Komohara Y. Role of tumor-associated macrophages in human malignancies: friend or foe? Pathol Int. 2016;66:491–505. doi:10.1111/pin.1244027444136
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Wang K, Mucida D, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature. 2012;491:254–258. doi:10.1038/nature1146523034650
   PubMed Web of Science ®Google Scholar
• Kong L, Zhou Y, Bu H, Lv T, Shi Y, Yang J. Deletion of interleukin-6 in monocytes/macrophages suppresses the initiation of hepatocellular carcinoma in mice. J Exp Clin Cancer Res. 2016;35:131. doi:10.1186/s13046-016-0444-627589954
   PubMed Web of Science ®Google Scholar
• Kuang D, Zhao Q, Peng C, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009;206:1327–1337. doi:10.1084/jem.2008217319451266
   PubMed Web of Science ®Google Scholar
• Deng YR, Liu WB, Lian ZX, Li X, Hou X. Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma. Oncotarget. 2016;7:38292–38305. doi:10.18632/oncotarget.943827203677
   PubMedGoogle Scholar